

shall award grants to, or enter into cooperative agreements with, Federal, State, and local agencies to improve coordination between public health laboratories and laboratories operated by law enforcement agencies, such as Customs and Border Protection and the Drug Enforcement Administration, to improve detection of synthetic opioids, including fentanyl and its analogues, as described in subsection (b).

**(b) Detection activities**

The Secretary, in consultation with the Director of the National Institute of Standards and Technology, the Director of the Centers for Disease Control and Prevention, the Attorney General of the United States, and the Administrator of the Drug Enforcement Administration, shall, for purposes of this section, develop or identify—

- (1) best practices for safely handling and testing synthetic opioids, including fentanyl and its analogues, including with respect to reference materials, instrument calibration, and quality control protocols;
- (2) reference materials and quality control standards related to synthetic opioids, including fentanyl and its analogues, to enhance—
  - (A) clinical diagnostics;
  - (B) postmortem data collection; and
  - (C) portable testing equipment utilized by law enforcement and public health officials; and
- (3) procedures for the identification of new and emerging synthetic opioid formulations and procedures for reporting those findings to appropriate law enforcement agencies and Federal, State, and local public health laboratories and health departments, as appropriate.

**(c) Laboratories**

The Secretary shall require recipients of grants or cooperative agreements under subsection (a) to—

- (1) follow the best practices established under subsection (b) and have the appropriate capabilities to provide laboratory testing of controlled substances, such as synthetic fentanyl, and biospecimens for the purposes of aggregating and reporting public health information to Federal, State, and local public health officials, laboratories, and other entities the Secretary deems appropriate;
- (2) work with law enforcement agencies and public health authorities, as practicable;
- (3) provide early warning information to Federal, State, and local law enforcement agencies and public health authorities regarding trends or other data related to the supply of synthetic opioids, including fentanyl and its analogues;
- (4) provide biosurveillance capabilities with respect to identifying trends in adverse health outcomes associated with non-fatal exposures; and
- (5) provide diagnostic testing, as appropriate and practicable, for non-fatal exposures of emergency personnel, first responders, and other individuals.

**(d) Authorization of appropriations**

To carry out this section, there is authorized to be appropriated \$15,000,000 for each of fiscal years 2019 through 2023.

(Pub. L. 115-271, title VII, § 7011, Oct. 24, 2018, 132 Stat. 4008.)

**Editorial Notes**

**CODIFICATION**

Section was enacted as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, also known as the SUPPORT for Patients and Communities Act, and not as part of the Public Health Service Act which comprises this chapter.

**§ 247d-11. State All Payer Claims Databases**

**(a) In general**

The Secretary shall make one-time grants to eligible States for the purposes described in subsection (b).

**(b) Uses**

A State may use a grant received under subsection (a) for one of the following purposes:

- (1) To establish a State All Payer Claims Database.
- (2) To improve an<sup>1</sup> existing State All Payer Claims Databases.<sup>1</sup>

**(c) Eligibility**

To be eligible to receive a grant under subsection (a), a State shall submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary specifies, including, with respect to a State All Payer Claims Database, at least specifics on how the State will ensure uniform data collection and the privacy and security of such data.

**(d) Grant period and amount**

Grants awarded under this section shall be for a period of 3-years,<sup>2</sup> and in an amount of \$2,500,000, of which \$1,000,000 shall be made available to the State for each of the first 2 years of the grant period, and \$500,000 shall be made available to the State for the third year of the grant period.

**(e) Authorized users**

**(1) Application**

An entity desiring authorization for access to a State All Payer Claims Database that has received a grant under this section shall submit to the State All Payer Claims Database an application for such access, which shall include—

(A) in the case of an entity requesting access for research purposes—

- (i) a description of the uses and methodologies for evaluating health system performance using such data; and
- (ii) documentation of approval of the research by an institutional review board, if applicable for a particular plan of research; or

(B) in the case of an entity such as an employer, health insurance issuer, third-party administrator, or health care provider, requesting access for the purpose of quality improvement or cost-containment, a description of the intended uses for such data.

<sup>1</sup> So in original.

<sup>2</sup> So in original. Probably should be “3 years.”

**(2) Requirements****(A) Access for research purposes**

Upon approval of an application for research purposes under paragraph (1)(A), the authorized user shall enter into a data use and confidentiality agreement with the State All Payer Claims Database that has received a grant under this subsection, which shall include a prohibition on attempts to reidentify and disclose individually identifiable health information and proprietary financial information.

**(B) Customized reports**

Employers and employer organizations may request customized reports from a State All Payer Claims Database that has received a grant under this section, at cost, subject to the requirements of this section with respect to privacy, security, and proprietary financial information.

**(C) Non-customized reports**

A State All Payer Claims Database that has received a grant under this section shall make available to all authorized users aggregate data sets available through the State All Payer Claims Database, free of charge.

**(3) Waivers**

The Secretary may waive the requirements of this subsection of a State All Payer Claims Database to provide access of entities to such database if such State All Payer Claims Database is substantially in compliance with this subsection.

**(f) Expanded access****(1) Multi-State applications**

The Secretary may prioritize applications submitted by a State whose application demonstrates that the State will work with other State All Payer Claims Databases to establish a single application for access to data by authorized users across multiple States.

**(2) Expansion of data sets**

The Secretary may prioritize applications submitted by a State whose application demonstrates that the State will implement the reporting format for self-insured group health plans described in section 1191d of title 29.

**(g) Definitions**

In this section—

(1) the term “individually identifiable health information” has the meaning given such term in section 1320d(6) of this title;

(2) the term “proprietary financial information” means data that would disclose the terms of a specific contract between an individual health care provider or facility and a specific group health plan, managed care entity (as defined in section 1396u-2(a)(1)(B) of this title) or other managed care organization, or health insurance issuer offering group or individual health insurance coverage; and

(3) the term “State All Payer Claims Database” means, with respect to a State, a database that may include medical claims, pharmacy claims, dental claims, and eligibility

and provider files, which are collected from private and public payers.

**(h) Authorization of appropriations**

To carry out this section, there is authorized to be appropriated \$50,000,000 for each of fiscal years 2022 and 2023, and \$25,000,000 for fiscal year 2024, to remain available until expended.

(July 1, 1944, ch. 373, title III, §320B, as added Pub. L. 116-260, div. BB, title I, §115(a), Dec. 27, 2020, 134 Stat. 2875.)

**Editorial Notes**

## CODIFICATION

Section 115(a) of div. BB of Pub. L. 116-260, which directed that section 320B (this section) be added at the end of part B of title III of the Public Health Service Act, was executed as directed, notwithstanding that section 320 of the Public Health Service Act (section 247e of this title) appears in part C of title III of the Act, resulting in section 320B of the Act preceding section 320.

PART C—HOSPITALS, MEDICAL EXAMINATIONS,  
AND MEDICAL CARE**Editorial Notes**

## CODIFICATION

Pub. L. 95-626, title I, §113(a)(1), Nov. 10, 1978, 92 Stat. 3562, struck out heading “Subpart I—General Provisions”.

Pub. L. 94-484, title IV, §407(a), Oct. 12, 1976, 90 Stat. 2268, added heading “Subpart I—General Provisions”.

**§ 247e. National Hansen’s Disease Programs Center****(a) Care and treatment**

(1) At or through the National Hansen’s Disease Programs Center (located in the State of Louisiana), the Secretary shall without charge provide short-term care and treatment, including outpatient care, for Hansen’s disease and related complications to any person determined by the Secretary to be in need of such care and treatment. The Secretary may not at or through such Center provide long-term care for any such disease or complication.

(2) The Center referred to in paragraph (1) shall conduct training in the diagnosis and management of Hansen’s disease and related complications, and shall conduct and promote the coordination of research (including clinical research), investigations, demonstrations, and studies relating to the causes, diagnosis, treatment, control, and prevention of Hansen’s disease and other mycobacterial diseases and complications related to such diseases.

(3) Paragraph (1) is subject to section 211 of the Department of Health and Human Services Appropriations Act, 1998.

**(b) Additional sites authorized**

In addition to the Center referred to in subsection (a), the Secretary may establish sites regarding persons with Hansen’s disease. Each such site shall provide for the outpatient care and treatment for Hansen’s disease and related complications to any person determined by the Secretary to be in need of such care and treatment.